Skip to main content
SpringerLink
Log in

Tenidap

  • New Drug Profile
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

Summary

  • ▲ Tenidap is the first of a new class of agents with anti-inflammatory and immunomodulatory activity in rheumatoid arthritis

  • ▲ It is a cytokine modulator and reduces production of certain proinflammatory cytokines including interleukins-1 and -6 and tumour necrosis factor-α

  • ▲ It also inhibits cyclo-oxygenase, decreasing the production of proinflammatory arachidonic acid derivatives

  • ▲ Parameters of disease control (grip strength, number of tender/swollen joints, pain, erythrocyte sedimentation rate, acute phase protein levels) in patients with rheumatoid arthritis were improved with tenidap therapy

  • ▲ Tenidap was more effective than representative nonsteroidal anti-inflammatory drugs (NSAIDs) as treatment for rheumatoid arthritis

  • ▲ Tenidap was at least as effective as combination therapy with NSAIDs and disease modifying anti-rheumatic drugs as treatment for rheumatoid arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moilanen E, Alanko J, Asmawi MZ, et al. CP-66,248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leucocytes in vitro. Eicosanoids 1988; 1: 35–9

    PubMed  CAS  Google Scholar 

  2. Pruzanski W, Kennedy BP, van den Bosch H, et al. Tenidap sodium inhibits secretory non-pancreatic phospholipase A2 synthesis by foetal rat calvarial osteoblasts. Med Inflamm 1995; 4: 67–70

    Article  CAS  Google Scholar 

  3. Blackburn WD, Loose LD, Heck LW, et al. Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase. Arthritis Rheum 1991 Feb; 34: 211–6

    Article  PubMed  CAS  Google Scholar 

  4. Kyan-Aung U, Lee TH, Haskard DO. The inhibitory effect of tenidap on leukocyte-endothelial cell adhesion. J Rheumatol 1993 Jun; 20: 1014–9

    PubMed  CAS  Google Scholar 

  5. Otterness IG, Bliven ML, Downs JT, et al. Inhibition of interleukin 1 synthesis by tenidap: a new drug for arthritis. Cytokine 1991; 3: 277–83

    Article  PubMed  CAS  Google Scholar 

  6. Martel-Pelletier J, Ounissi H, Cloutier J-M. Tenidap effectively reduces cytokine synthesis and expression by human rheumatoid arthritis synovium [abstract]. Arthritis Rheum 1994 Sep; 37 Suppl.: 309

    Google Scholar 

  7. McNiff P, Svensson L, Pazoles CJ, et al. Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro: I. Mechanism and evidence of functional significance. J Immunol 1994 Sep 1; 153: 2180–93

    PubMed  CAS  Google Scholar 

  8. Miltenburg AMM, Dolhain RJEM, de Kuiper R, et al. Tenidap inhibits T-cell proliferation, cytokine-production, and the induction of mRNA encoding TNF-alpha and IFN-gamma. Arthritis Rheum 1994 Sep; 37 (Suppl.): 384

    Article  Google Scholar 

  9. Smith DD, Cohick CB, Lindsley HB, et al. Inhibition by tenidap of inducible HLA class II expression on cultured human synoviocytes and the human T cell line, HUT 78. Clin Res 1994 Oct; 42: 384

    Google Scholar 

  10. Dingle JT, Leeming MRG, Martindale JJ. Effect of tenidap on cartilage integrity in vitro. Ann Rheum Dis 1993 Apr; 52: 292–9

    Article  PubMed  CAS  Google Scholar 

  11. Pelletier J-P, McCollum R, DiBattista J, et al. Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 1993 Nov; 36: 1517–27

    Article  PubMed  CAS  Google Scholar 

  12. Mattey DL, Evans E, Dawes PT. The effects of tenidap on cytokine induced proliferation of human synovial fibroblasts in vitro. Ann Rheum Dis 1994 Apr; 53: 250–5

    Article  PubMed  CAS  Google Scholar 

  13. Otterness IG, Pazoles PP, Moore PF, et al. C-reactive protein as an index of disease activity. Comparison of tenidap, cyclophosphamide and dexamethasone in rat adjuvant arthritis. J Rheumatol 1991; 18: 050–11

    Google Scholar 

  14. Fernandes JC, Martel-Pelletier J, Otterness IG, et al. Effects of tenidap on canine experimental osteoarthritis: I — morphological analysis and metalloprotease activity. Arthritis Rheum Sep 1995; 38: 1290–303

    Article  CAS  Google Scholar 

  15. Loose LD, Sipe JD, Kirby DS, et al. Reduction of acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drug. Br J Rheumatol 1993 Jun; 32(Suppl. 3): 19–25

    Article  PubMed  Google Scholar 

  16. Littman BH, Drury CE, Zimmerer RO, et al. Rheumatoid arthritis treated with tenidap and piroxicam: clinical associations with cytokine modulation by tenidap. Arthritis Rheum 1995 Jan; 38: 29–37

    Article  PubMed  CAS  Google Scholar 

  17. Littman BH, Drury CE, Schumacher R, et al. In vivo reduction of rheumatoid arthritis synovial tissue metalloproteinase mRNA levels by tenidap [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 224

    Google Scholar 

  18. Loose LD, Blackburn WD, Sipe JD, et al. Tenidap but not naproxen reduces synovitis in RA: a2-week study in patients with knee effusions [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 225

    Google Scholar 

  19. Loose LD, Sipe JD, Weiner ES et al. Reduction in CRP in tenidap, but not NSAID-treated osteoarthritis (OA) patients [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 225

    Google Scholar 

  20. Sharif M, Meadows K, Dieppe PA. The effects of a 3-substituted 2-oxindole (tenidap) on a serum marker of cartilage degradation in osteoarthritis. Arthritis Rheum 1994 Sep; 37 (Suppl.): 345

    Google Scholar 

  21. Gardner MJ, Wilner KD, Hansen RA, et al. Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects. Br. J Clin Pharmacol 1995; 39: 11S–5S

    CAS  Google Scholar 

  22. Caldwell JR, Kirby DS, Gardner MJ, et al. The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Br J Pharmacol 1995; 39: 3S–9S

    Article  Google Scholar 

  23. Davis JS, Loose L, Borger AP. Clinical efficacy of CP-66,248 [5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide] in osteoarthritis (OA) [abstract]. Arthritis Rheum 1988; 31(Suppl. 4): B78

    Google Scholar 

  24. Sunshine A, Olson NZ, Zighelboim I, et al. Analgesic efficacy of tenidap vs. naproxen for the treatment of postepisiotomy pain [abstract]. 95th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, New Orleans 1994; 128

  25. Loose LD, Wilhelm FE, Kraska AR, et al. Double-blind, placebo-controlled, dose-response study of tenidap in rheumatoid arthritis [abstract]. Clin Rheumatol 1994 Jun; 13: 354–5

    Google Scholar 

  26. Kirby DS, Loose LD, Weiner ES, et al. Tenidap vs piroxicam vs piroxicam plus hydroxychloroquine in rheumatoid arthritis: results of a 2-year trial [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 225

    Google Scholar 

  27. Genant HK, Kirby DS, Pickering EA, et al. Tenidap slows x-ray progression in rheumatoid arthritis [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 224

    Google Scholar 

  28. Kirby DS, Loose LD, Burnside R, et al. A close look at tenidap vs naproxen treatment of rheumatoid arthritis [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 225

    Google Scholar 

  29. Leeming MRG, Tenidap European study group. A 2-year study of tenidap compared with auranofin and diclofenac in the treatment of early rheumatoid arthritis [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 224

    Google Scholar 

  30. Wylie G, Appelboom T, Bolten W, et al. A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial. Br J Rheumatol 1995; 34: 554–63

    Article  PubMed  CAS  Google Scholar 

  31. Pluck ND, Tenidap early RA study group. A 56 week study of tenidap vs diclofenac in rheumatoid arthritis [abstract]. Arthritis Rheum 1994 Sep; 37 Suppl.: 336

    Google Scholar 

  32. Breedveld F. Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis. Scand J Rheumatol 1994; 23(Suppl. 100): 31–44

    Article  Google Scholar 

  33. Turner RR, Kirby DS, Loose ES et al. The effect of tenidap on RA patient quality of life; a meta-analysis of the arthritis impact measurement scales (AIMS) [abstract]. Rheumatol Eur 1995; 24(Suppl. 3): 208

    Google Scholar 

  34. Pfizer. Data on file, 1995

  35. Apseloff G, Wilner KD, Gerber N. Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers. Br J Clin Pharmacol 1995; 39: 29S–33S

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand

    Diana Faulds & Stephanie Irvine

Authors
  1. Diana Faulds
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie Irvine
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faulds, D., Irvine, S. Tenidap. Clin. Immunother. 5, 161–167 (1996). https://doi.org/10.1007/BF03259321

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259321

Keywords

Search

Navigation